Botanix Pharmaceuticals to Initiate Papulopustular Rosacea Study

  • Sep 16, 2019 AEST
  • Team Kalkine

Botanix Pharmaceuticals Limited (ASX: BOT) is set to enter Phase 1b papulopustular rosacea study. BTX 1702, the new product, leverages Botanix’s proprietary drug delivery system PermetrexTM with synthetic cannabidiol. Recent mechanistic data generated by Botanix has demonstrated that synthetic cannabidiol exerts powerful anti-inflammatory and antimicrobial actions in skin.

  • Study would commence in Q4 CY2019.
  • BTX 1702 expands dermatology pipeline of the company.
  • Anti-inflammatory and antimicrobial actions are critical in treating rosacea.

By 11:56 AM AEST, BOT was trading at A$0.25, no change relative to the previous close.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.



All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK